Kalohexis' Dual MC3R/MC4R Agonist Shows Promising Weight Loss Data in Primates
Event summary
- Kalohexis presented data at ICO 2026 showing dual MC3R/MC4R activation drives weight loss, limits rebound, and preserves lean mass in obese nonhuman primates.
- The company's oral dual MC3R/MC4R agonist, 710GO, is currently in a Phase 1 clinical trial for general obesity.
- Kalohexis was spun out of Endevica Bio in March 2026 and focuses on metabolic disease care via the melanocortin system.
The big picture
Kalohexis' focus on the melanocortin system represents a novel approach to metabolic disease care, potentially offering more durable weight loss solutions. The company's dual MC3R/MC4R activation mechanism aims to address key limitations of current obesity treatments, such as weight rebound and muscle loss. Success in this space could position Kalohexis as a significant player in the growing market for advanced metabolic therapies.
What we're watching
- Clinical Progress
- How the Phase 1 trial of 710GO will progress and whether it can demonstrate similar efficacy in humans as seen in nonhuman primates.
- Market Differentiation
- Whether Kalohexis can position 710GO as a healthier and more durable alternative to existing weight loss treatments.
- Pipeline Expansion
- The pace at which Kalohexis advances its second lead program, mifomelatide, for cancer cachexia.
Related topics